Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Risk of out-of-hospital cardiac arrest in patients with rheumatoid arthritis: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Mortality and ventricular arrhythmia after acute myocarditis: a nationwide registry-based follow-up study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

OBJECTIVE: To prospectively validate the CT-Valve score, a new risk score designed to identify patients with valvular heart disease at a low risk of coronary artery disease (CAD) who could benefit from multislice CT (MSCT) first instead of coronary angiography (CAG).

METHODS: This was a prospective cohort study of patients referred for valve surgery in the Capital Region of Denmark and Odense University Hospital from the 1 February 2015 to the 1 February 2017. MSCT was implemented for patients with a CT-Valve score ≤7 at the referring physician's discretion. Patients with a history of CAD or chronic kidney disease were excluded. The primary outcome was the proportion of patients needing reevaluation with CAG after MSCT and risk of CAD among the patients determined to be low to intermediate risk.

RESULTS: In total, 1149 patients were included. The median score was 9 (IQR 3) and 339 (30%) had a score ≤7. MSCT was used for 117 patients. Of these 29 (25%) were reevaluated and 9 (7.7%) had CAD. Of the 222 patients with a score ≤7 that did not receive an MSCT, 14 (6%) had significant CAD. The estimated total cost of evaluation among patients with a score ≤7 before implementation was €132 093 compared with €79 073 after, a 40% reduction. Similarly, estimated total radiation before and after was 608 mSv and 362 mSv, a 41% reduction. Follow-up at a median of 32 months (18-48) showed no ischaemic events for patients receiving only MSCT.

CONCLUSION: The CT-Valve score is a valid method for determining risk of CAD among patients with valvular heart disease. Using a score ≤7 as a cut-off for the use of MSCT is safe and cost-effective.

TidsskriftOpen Heart
Udgave nummer2
StatusUdgivet - 5 okt. 2020

Bibliografisk note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 61009662